Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
38 hedge funds and large institutions have $1.29M invested in Viracta Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
5% less funds holding
Funds holding: 40 → 38 (-2)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
74% less capital invested
Capital invested by funds: $4.91M → $1.29M (-$3.61M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$183K |
| 2 |
HF
HRT Financial
New York
|
+$50.9K |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$25.1K |
| 4 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$15.8K |
| 5 |
Renaissance Technologies
New York
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.97M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$75.8K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$40.2K |
| 4 |
Morgan Stanley
New York
|
-$38.1K |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$33.5K |
VIRX Hedge Fund Activity: Q3 2024 in Review
38 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2024, worth a combined $1.29M — down 74% from $4.91M a quarter earlier.
Fund positioning in VIRX was balanced in Q3 2024: 10 funds opened new positions, 10 closed out, 6 added to existing stakes and 7 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $183K. The largest seller was BVF Inc, exiting entirely with an estimated $1.97M sold.
- 38 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2024, down from 40 in Q2 2024.
- Funds reported $1.29M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2024, down 74% quarter-over-quarter.
- 10 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2024 and 10 closed out, a net change of 0 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2024 was Stonepine Capital Management, an estimated $183K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2024 was BVF Inc, an estimated $1.97M sold.
Based on aggregated 13F filings for Q3 2024.